Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with enterohemorrhagic Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 5010-5013

  Secher, T ^a,b,c,d   Shima, A ^a,b,c,d   Hinsinger, K ^e   Cintrat, J C ^e   Johannes, L ^c,f,g   Barbier, J ^h   Gillet, D ^h   Oswald, E ^a,b,c,d,i  

^a CEMAGREF   (France)

^b INSERM   (France)

^c CNRS   (France)

^d Université Paul Sabatier   (France)

^e CEA   (France)

^f INSTITUT CURIE   (France)

^g CNRS UMR3666   (France)

^h Institute Frederic Joliot   (France)

ⁱ CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; RETRO 2 CYCL; RICIN; STREPTOMYCIN SULFATE; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2; 2-(((5-METHYL-2-THIENYL)METHYLENE)AMINO)-N-PHENYLBENZAMIDE; BENZAMIDE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; EUKARYOTIC CELL; HELA CELL LINE; IN VITRO STUDY; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MOUSE; MOUTH INFECTION; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VERO CELL LINE; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; DRUG EFFECTS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPIDEMIC; ESCHERICHIA COLI INFECTIONS; EUROPE; GENETICS; HEMOLYTIC-UREMIC SYNDROME; HUMAN; PATHOGENICITY;

ANIMALS; BENZAMIDES; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EUROPE; HELA CELLS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICE; MICE, INBRED BALB C; SHIGA TOXIN 2; THIOPHENES; VERO CELLS;

EID: 84939814518     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00455-15     Document Type: Article

References (15)

1. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086. http://dx.doi.org/10.1016/S0140-6736(05)71144-2.
2. Noris M, Remuzzi G. 2009. Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676-1687. http://dx.doi.org/10.1056/NEJMra0902814.
3. Sandvig K, van Deurs B. 2005. Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther 12:865-872. http://dx.doi.org/10.1038/sj.gt.3302525.
4. Johansen BK, Wasteson Y, Granum PE, Brynestad S. 2001. Mosaic structure of Shiga-toxin-2-encoding phages isolated from Escherichia coli O157:H7 indicates frequent gene exchange between lambdoid phage genomes. Microbiology 147:1929-1936.
5. Neely MN, Friedman DI. 1998. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of Shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol 28:1255-1267. http://dx.doi.org/10.1046/j.1365-2958.1998.00890.x.
6. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. 2009. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 53:259-272. http://dx.doi.org/10.1053/j.ajkd.2008.07.038.
7. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. 2012. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 55:33-41. http://dx.doi.org/10.1093/cid/cis299.
8. Buchholz U, Bernard H, Werber D, Bohmer MM, Remschmidt C, Wilking H, Delere Y, an der Heiden M, Adlhoch C, Dreesman J, Ehlers J, Ethelberg S, Faber M, Frank C, Fricke G, Greiner M, Hohle M, Ivarsson S, Jark U, Kirchner M, Koch J, Krause G, Luber P, Rosner B, Stark K, Kuhne M. 2011. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 365:1763-1770. http://dx.doi.org/10.1056/NEJMoa1106482.
9. Robert Koch Institute. 2011. Final presentation and evaluation of the epidemiological findings in the EHEC O104:H4 outbreak, Germany, 2011. Robert Koch Institute, Berlin, Germany. http://www.rki.de/EN/Home/EHEC-final-report.pdf?--blob=publicationFile.
10. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Moller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK. 2011. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365:709-717. http://dx.doi.org/10.1056/NEJMoa1106920.
11. Stechmann B, Bai SK, Gobbo E, Lopez R, Merer G, Pinchard S, Panigai L, Tenza D, Raposo G, Beaumelle B, Sauvaire D, Gillet D, Johannes L, Barbier J. 2010. Inhibition of retrograde transport protects mice from lethal ricin challenge. Cell 141:231-242. http://dx.doi.org/10.1016/j.cell.2010.01.043.
12. Shimizu K, Asahara T, Nomoto K, Tanaka R, Hamabata T, Ozawa A, Takeda Y. 2003. Development of a lethal Shiga toxin-producing Escherichia coli-infection mouse model using multiple mitomycin C treatment. Microb Pathog 35:1-9. http://dx.doi.org/10.1016/S0882-4010(03)00065-2.
13. McGannon CM, Fuller CA, Weiss AA. 2010. Different classes of antibiotics differentially influence Shiga toxin production. Antimicrob Agents Chemother 54:3790-3798. http://dx.doi.org/10.1128/AAC.01783-09.
14. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH. 2003. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337-1344. http://dx.doi.org/10.1001/jama.290.10.1337.
15. Lopez EL, Contrini MM, Glatstein E, Gonzalez Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S. 2010. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 54:239-243. http://dx.doi.org/10.1128/AAC.00343-09.